ArticleJournal of breast cancer2015
Risk of Second Primary Malignancy in Breast Cancer Survivors: A Nested Population-Based Case-Control Study.
Article in Journal of breast cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Risks of second non-breast primaries following breast cancer in women: a systematic review and meta-analysis.Breast cancer research : BCR · 2023Pooled it
- Risk of second primary cancer among breast cancer patients: A systematic review and meta-analysis.Frontiers in oncology · 2022Pooled it
- Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT.Health technology assessment (Winchester, England) · 2020Trial
- Links between Breast and Thyroid Cancer: Hormones, Genetic Susceptibility and Medical Interventions.Cancers · 2022Review
- The co-occurrence of both breast- and differentiated thyroid cancer: incidence, association and clinical implications for daily practice.BMC cancer · 2022Article
- Risk Prediction of Second Primary Malignancies in Primary Early-Stage Ovarian Cancer Survivors: A SEER-Based National Population-Based Cohort Study.Frontiers in oncology · 2022Article
- Deciphering the Risk of Developing Second Primary Thyroid Cancer Following a Primary Malignancy-Who Is at the Greatest Risk?Cancers · 2021Article
- Second primary malignancies of eye and ocular adnexa after a first primary elsewhere in the body.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2021Article
- Differential Second Primary Malignancy Occurrence After Breast Cancer According to HER2 Status: A Population-Based Study.International journal of general medicine · 2021Article
- Effect of breast cancer as the first or second primary cancer on the prognosis of women with thyroid cancer: a SEER database analysis.Translational cancer research · 2020Article
- Article
- Clinicopathological features, survival and risk in breast cancer survivors with thyroid cancer: an analysis of the SEER database.BMC public health · 2019Article
- A Review on Curability of Cancers: More Efforts for Novel Therapeutic Options Are Needed.Cancers · 2019Review
- Prediagnosis obesity and secondary primary cancer risk in female cancer survivors: A national cohort study.Cancer medicine · 2019Article
- Periampullary Metastases from Breast Cancer: A Case Report and Literature Review.Case reports in oncological medicine · 2019Article
- Retrospective Analysis of Patients with Synchronous Primary Breast and Thyroid Carcinoma.European journal of breast health · 2018Article
- Secondary cancer-incidence risk estimates for external radiotherapy and high-dose-rate brachytherapy in cervical cancer: phantom study.Journal of applied clinical medical physics · 2016Article
- Evaluation of Diagnostic Accuracy and Impact of Preoperative Positron Emission Tomography/Computed Tomography in the Management of Early Operable Breast Cancers.Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, IndiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeEvolving therapies have improved the prognoses of patients with breast cancer; and currently, the number of long-term survivors is continuously increasing. However, these patients are at increased risk of developing a second cancer. Thus, late side effects are becoming an important issue. In this study, we aimed to investigate whether patient and tumor characteristics, and treatment type correlate with secondary tumor risk.
methodsThis case-control study included 305 patients with a diagnosed second malignancy after almost 6 months after the diagnosis of primary breast cancer and 1,525 controls (ratio 1:5 of cases to controls) from a population-based cohort of 6,325 women. The control patients were randomly selected from the cohort and matched to the cases according to age at diagnosis, calendar period of diagnosis, disease stage, and time of follow-up.
resultsBRCA1 or BRCA2 mutation, human epidermal growth factor receptor 2 (HER2)+ status, chemotherapy, and radiotherapy were related to increased risk of developing a second cancer, whereas hormonotherapy showed a protective effect. Chemotherapy, radiotherapy, and estrogenic receptor level <10% increased the risk of controlateral breast cancer. HER2+ status increased the risk of digestive system and thyroid tumors, while BRCA1 or BRCA2 mutation increased the risk of cancer in the genital system.
conclusionBreast cancer survivors are exposed to an excess of risk of developing a second primary cancer. The development of excess of malignancies may be related either to patient and tumor characteristics, such as BRCA1 or BRCA2 mutation and HER2+ status, or to treatments factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.